Table 1. Effect of the treatment oxaliplatin and/or metformin (100 or 200 mg/kg) on body weight in A) non-diabetic mice (experiment I) and B) diabetic mice (experiment II).

A)	Baseline BWt (g)	Final BWt (g)	% Change in BWt
Saline	31.1±2.52	33.38±0.42	7.33±0.42
DMH	31.68±0.36	33.94±0.4	7.14±0.52
Oxaliplatin	30.41±0.73	28.78±0.46	−5.25±0.45
Metformin (100 mg/kg)	30.04±0.71	31.98±0.88	6.48±0.23
Metformin (200 mg/kg)	29.84±0.75	31.08±1.37	3.98±0.26
Combination 1	28.26±1.91	30.38±0.64	7.58±0.49
Combination 2	29.82±1.73	32.3±1.02	8.6±0.27
B)
Saline	34.43±0.5	31.86±1.24	−7.45±0.32
DMH	36.43±0.44	31.08±0.67	−14.67±0.63
Oxaliplatin	35.46±0.48	28.64±0.48	−19.24±1.32
Metformin (100 mg/kg)	36.3±2.23	31.66±0.76	−30.66±0.24
Metformin (200 mg/kg)	33.66±2.17	29.46±0.65	−12.78±0.57
Combination 1	35.5±2.16	30.4±1.21	−14.36±1.17
Combination 2	38.3±2.53	30.56±0.92	−20.2±1.64

Mice [except saline group] were injected with 1,2-dimethylhydrazine (DMH) weekly for 15 week to induce colon cancer then treated with oxaliplatin and/or metformin (100 or 200 mg/kg) for 4 weeks. Percent change in BWt was calculated using a formula: % change BWt  =  [(final BWt- baseline BWt)/baseline BWt] x 100. Baseline BWt: was recorded at the end of week 4 and final BWt was recorded at the end of week 24. Results are expressed as mean ± S.E.M and analyzed using two-way ANOVA followed by Tukey's post-hoc test at P<0.05. The mean baseline body weight in experiment I was compared to that recorded in experiment II using unpaired student's t test.